Biomea Fusion Announces Phase 1 Results for BMF-650, Oral GLP-1 Receptor Agonist
FROM THE WIRE · MANILATIMES.NET
Mean weight reduction ranged from 1.5% to 3.2% at Day 29 across Cohorts 1-4, compared with 0.1% for pooled placebo.No severe or serious TEAEs, no TEAE-related dose modifications, and no TEAE-related discontinuations among all BMF-650-treated MAD participants.A rapid one-step…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive Phase 1 results support clinical development of a new oral GLP-1 drug with favorable tolerability profile.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Mean weight reduction ranged from 1.5% to 3.2% at Day 29 versus 0.1% for placebo across Cohorts 1-4.
- 02No severe or serious adverse events among BMF-650-treated participants, with no dose modifications or discontinuations due to side effects.
- 03Rapid one-step titration to 400 mg daily target dose was well tolerated with mild adverse events, nausea and vomiting each in only 12.5% of…